ResMed

By Dave Muoio November 10, 2017
SleepScore Labs — a joint venture between ResMed, Dr. Oz Media, and Pegasus Capital Advisors — has announced a new non-contact sleep improvement device available for consumer purchase. From the user’s bedside, the SleepScore Max ($149.99) measures a number of different sleep-affecting variables including respiration, body movement, duration, and environmental qualities such as temperature and...
By Laura Lovett November 7, 2017
Monitoring sleep disorders while traveling just became easier this week after the San Diego based company, ResMed announced that the AirMini, a miniature CPAP device, will now to be able to connect to the AirView, a remote patient monitoring platform. The new feature allows clinicians to remotely monitor patients’ nightly data, verify adherence and find therapy issues, according to the press...
By Heather Mack March 31, 2017
In the first quarter of 2017, we tracked seven digital health-related FDA clearances. While the list isn’t long, it’s varied and relatively novel – from app and device integrations for diabetes treatment to a vest that maps cardiac rhythms. The beginning of this year also rang in some big changes, as the Trump Administration took root and nominated Dr. Scott Gottlieb as FDA deputy commissioner....
By Heather Mack March 22, 2017
ResMed, maker of devices and software to improve sleep and chronic respiratory conditions, has teamed up with Adaptive Sound Technologies to offer the sound machine through its portfolio of sleep technology products.  “With a leading global position in sleep technology and proven track record of offering innovative products and solutions to improve the health and quality of life, ResMed is...
By Heather Mack February 8, 2017
The remote patient monitoring market saw a big jump in the last year, with 7.1 million patients in 2016 enrolled in some form of digital health program featuring connected medical devices as a core part of their care plan, according to new data. Swedish market research firm Berg Insight, which specializes in IoT verticals, tracked a 44 percent jump in remotely monitored patients last year. While...
By Heather Mack January 25, 2017
San Diego, California-based ResMed, maker of connected respiratory devices, announced strong results for its quarter ending on December 31, with over $530 million in revenue representing a 17 percent increase year over year. On a call with investors, ResMed CEO Mick Farrell said the growth was driven by sales from Brightree – the cloud-based software company ResMed acquired last year for $800...
By Jonah Comstock January 12, 2017
Two digital health companies focused on sleep published data this week that highlighted the efficacy of their respective platforms, bringing continued attention to the space after a CES week where sleep was a major focus. A whitepaper by Pricewaterhouse Cooper showed that ResMed’s myAir improved CPAP adherence while a paper in the Journal of Clinical Sleep Medicine found that EarlySense’s new...
By Heather Mack January 9, 2017
San Diego, California-based ResMed has received FDA 510(k) clearance for its small, portable continuous positive airway pressure (CPAP) device, the AirMini. The announcement was made during the JP Morgan conference in San Francisco today. Designed to be used as an secondary device –  particularly during travel or any other time the user doesn’t have access to or doesn’t want to bring their full-...
By Jonah Comstock January 6, 2017
In addition to the many device launches, several digital health companies use CES (formerly known as the Consumer Electronic Show) in Las Vegas as an opportunity to announce updates and major partnerships and collaborations. Read on for the biggest non-launch health news from the show. Lots of news from Fitbit Wearable giant Fitbit announced a number of partnerships as well as updates to its app...
By Jonah Comstock October 25, 2016
A new study from San Diego-based sleep monitoring company ResMed shows that patients on positive airway pressure (PAP) therapy for their sleep apnea are more likely to be compliant when they manage their therapy with a patient-facing app.  The study of 128,000 patients, which is being presented tomorrow at the annual meeting of the American College of Chest Physicians, wasn’t randomized but did...